Literature DB >> 28923224

An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.

Naruhiko Ikoma1, Kanwal Raghav1, George Chang2.   

Abstract

There have been remarkable advances in the treatment of metastatic colorectal cancer over the past 20 years, chiefly achieved by development of new active drugs and establishment of effective systemic therapy regimens. Multidisciplinary care of resectable liver disease with use of perioperative systemic therapy and superior liver resection has resulted in prolonged survival of select patients. Median overall survival has significantly improved with the modern multiagent regimens. This article reviews recent high-quality randomized clinical trials that were conducted to address optimal treatment of advanced and metastatic colorectal carcinoma, mainly focused on initially inoperable metastatic disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Metastatic colorectal cancer; Monoclonal antibody; Randomized controlled trial

Mesh：

Substances：

Year:  2017        PMID： 28923224      PMCID： PMC5648005          DOI： 10.1016/j.soc.2017.05.007

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  66 in total

1.  Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?

Authors:  Bert H O'Neil; Alan P Venook
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

Review 2.  XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.

Authors:  Yu Guo; Bing-Hong Xiong; Tao Zhang; Yong Cheng; Li Ma
Journal:  Cancer Invest       Date:  2016-02-11       Impact factor: 2.176

3.  Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

Authors:  Josep Tabernero; Takayuki Yoshino; Allen Lee Cohn; Radka Obermannova; Gyorgy Bodoky; Rocio Garcia-Carbonero; Tudor-Eliade Ciuleanu; David C Portnoy; Eric Van Cutsem; Axel Grothey; Jana Prausová; Pilar Garcia-Alfonso; Kentaro Yamazaki; Philip R Clingan; Sara Lonardi; Tae Won Kim; Lorinda Simms; Shao-Chun Chang; Federico Nasroulah
Journal:  Lancet Oncol       Date:  2015-04-12       Impact factor: 41.316

4.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

5.  Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Authors:  Robert J Mayer; Eric Van Cutsem; Alfredo Falcone; Takayuki Yoshino; Rocio Garcia-Carbonero; Nobuyuki Mizunuma; Kentaro Yamazaki; Yasuhiro Shimada; Josep Tabernero; Yoshito Komatsu; Alberto Sobrero; Eveline Boucher; Marc Peeters; Ben Tran; Heinz-Josef Lenz; Alberto Zaniboni; Howard Hochster; James M Cleary; Hans Prenen; Fabio Benedetti; Hirokazu Mizuguchi; Lukas Makris; Masanobu Ito; Atsushi Ohtsu
Journal:  N Engl J Med       Date:  2015-05-14       Impact factor: 91.245

6.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.

Authors:  E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper
Journal:  J Clin Oncol       Date:  2001-11-01       Impact factor: 44.544

7.  Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Authors:  G Masi; L Salvatore; L Boni; F Loupakis; C Cremolini; L Fornaro; M Schirripa; S Cupini; C Barbara; V Safina; C Granetto; E Fea; L Antonuzzo; C Boni; G Allegrini; S Chiara; D Amoroso; A Bonetti; A Falcone
Journal:  Ann Oncol       Date:  2015-01-18       Impact factor: 32.976

8.  Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Authors:  C-H Köhne; J De Greve; J T Hartmann; I Lang; P Vergauwe; K Becker; D Braumann; E Joosens; L Müller; J Janssens; C Bokemeyer; P Reimer; H Link; E Späth-Schwalbe; H-J Wilke; H Bleiberg; J Van Den Brande; M Debois; U Bethe; E Van Cutsem
Journal:  Ann Oncol       Date:  2007-12-06       Impact factor: 32.976

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).

Authors:  J Souglakos; N Ziras; S Kakolyris; I Boukovinas; N Kentepozidis; P Makrantonakis; S Xynogalos; Ch Christophyllakis; Ch Kouroussis; L Vamvakas; V Georgoulias; A Polyzos
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640
View more
  8 in total

Review 1.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 2.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

3.  Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A.

Authors:  Satya Narayan; Asif Raza; Iqbal Mahmud; Nayeong Koo; Timothy J Garrett; Mary E Law; Brian K Law; Arun K Sharma
Journal:  iScience       Date:  2022-06-03

4.  5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING.

Authors:  Jingru Tian; Dingyao Zhang; Vadim Kurbatov; Qinrong Wang; Yadong Wang; Dorthy Fang; Lizhen Wu; Marcus Bosenberg; Mandar D Muzumdar; Sajid Khan; Qianjin Lu; Qin Yan; Jun Lu
Journal:  EMBO J       Date:  2021-02-22       Impact factor: 14.012

Review 5.  Simultaneous curative resection of double colorectal carcinoma with synchronous bilobar liver metastases.

Authors:  Emilio De Raffele; Mariateresa Mirarchi; Dajana Cuicchi; Ferdinando Lecce; Claudio Ricci; Riccardo Casadei; Bruno Cola; Francesco Minni
Journal:  World J Gastrointest Oncol       Date:  2018-10-15

6.  Rare Signet Ring Cell Adenocarcinoma of the Colon Metastasis to the Orbit.

Authors:  Colin Bacorn; Lily Koo Lin
Journal:  Case Rep Ophthalmol Med       Date:  2020-02-25

Review 7.  A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients.

Authors:  Lasse D Jensen; Delmy Oliva; Bengt-Åke Andersson; Freddi Lewin
Journal:  Cancer Metastasis Rev       Date:  2021-12-27       Impact factor: 9.264

8.  Thymoquinone Radiosensitizes Human Colorectal Cancer Cells in 2D and 3D Culture Models.

Authors:  Samar Al Bitar; Farah Ballout; Alissar Monzer; Mariam Kanso; Nour Saheb; Deborah Mukherji; Walid Faraj; Ayman Tawil; Samer Doughan; Maher Hussein; Wassim Abou-Kheir; Hala Gali-Muhtasib
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.